Kevin Maskell

CEO/CSO and Founder at Bioarchitech

Presenter

Bioarchitech mines the genomes of viruses for multifunctional immunotherapy assets to treat cancer. Led by its scientific founders in Oxford, UK, Bioarchitech has two assets ready to take forward to clinical studies 1) a modified virus with a novel nanobody transgene for last-stage cancer, 2) an RNA therapy that turns tumours into their own vaccine, in situ, for early-stage cancer. Bioarchitech has in vivo proof-of-concept data, patents and strong business cases for its technologies.